|
Variable
|
Training cohort
|
Validation cohort
|
|---|
|
(n = 2702)
|
(n = 1159)
|
|---|
|
Medium age at diagnosis, (25th–75th percentile)
|
62 (53–69)
|
60 (51–69)
|
|
Race n (%)
|
|
White
|
1869 (69.2)
|
808 (71.2)
|
|
Black
|
591 (22.1)
|
243 (20.2)
|
|
Other
|
242 (8.6)
|
108 (8.6)
|
|
Marital status n (%)
|
|
Married
|
1257 (47.6)
|
561 (48.3)
|
|
Single
|
586 (22.3)
|
261 (22.7)
|
|
SDW
|
736 (25.6)
|
293 (25.5)
|
|
Unknown
|
123 (4.6)
|
44 (3.5)
|
|
Insurance record n (%)
|
|
Yes
|
2584 (95.4)
|
1117 (96.3)
|
|
No
|
118 (4.6)
|
42 (3.7)
|
|
Tumor size n (%)
|
|
≤ 50 mm
|
710 (23.1)
|
313 (23.8)
|
|
> 50 mm
|
1596 (61.4)
|
677 (61.6)
|
|
Unknown
|
396 (15.6)
|
169 (14.6)
|
|
Pathological grade n (%)
|
|
I
|
169 (6.4)
|
76 (6.0)
|
|
II
|
345 (12.0)
|
135 (11.4)
|
|
III
|
1193 (43.0)
|
527 (44.5)
|
|
IV
|
995 (38.7)
|
421 (38.2)
|
|
Histological type n (%)
|
|
Sarcoma
|
76 (4.3)
|
20 (2.8)
|
|
Leiomyosarcoma
|
532 (28.3)
|
215 (26.6)
|
|
Adenosarcoma
|
124 (4.4)
|
45 (3.8)
|
|
Stromal sarcoma
|
455 (14.1)
|
207 (15.5)
|
|
Carcinosarcoma
|
1515 (48.8)
|
672 (51.3)
|
|
SEER stage n (%)
|
|
Localized
|
1116 (37.4)
|
537 (42.5)
|
|
Regional
|
825 (29.1)
|
321 (28.2)
|
|
Distant
|
761 (33.5)
|
301 (29.3)
|
|
AJCC stage n (%)
|
|
I
|
1225 (41.0)
|
573 (45.1)
|
|
II
|
236 (9.7)
|
84 (8.1)
|
|
III
|
572(20.0)
|
222 (20.0)
|
|
IV
|
669 (29.3)
|
280 (26.9)
|
|
Surgery status n (%)
|
|
Yes
|
2516 (90.8)
|
1090 (92.4)
|
|
No/unknown
|
186 (9.2)
|
69 (7.6)
|
|
Radiotherapy status n (%)
|
|
Yes
|
782 (26.3)
|
313 (24.6)
|
|
No/unknown
|
1920 (73.7)
|
846 (75.4)
|
|
Chemotherapy status n (%)
|
|
Yes
|
1420 (52.4)
|
598 (53.2)
|
|
No/unknown
|
1282 (47.6)
|
561 (46.8)
|
